Photo by nci from unsplash
NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute… Click to show full abstract
NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain; Discovery Tower, Singapore Eye Research Institute, The Academia, Singapore, Singapore; Department of Orthopedics, University Medical Center, Utrecht University, Utrecht, The Netherlands; Department of Health Technology, Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, Denmark; Department of Regenerative Biomaterials, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona, Verona, Italy; Gloriana Therapeutics, Inc. (formerly NsGene Inc.), Providence, Rhode Island, USA
Journal Title: Expert Opinion on Biological Therapy
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!